Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...

Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...

CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...

Biotech stocks are among the few industry groups producing breakouts and buyable stocks in an uncertain market. Vertex stock ...

SAN JOSE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- GTC— NVIDIA today announced a major release of new NVIDIA Cosmos™ world foundation models (WFMs), introducing an open and fully customizable ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX ...

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...

About the company: SurgeGraph Vertex is an SEO AI writing tool with a mission to redefine content writing through humanized, ...

Taking care of my personal health remains a top priority, however, I have also turned my attention to encouraging others to prioritize their health by raising awareness of my experiences. I understand ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex’s Orkambi (lumacaftor+ivacaftor) cystic fibrosis drug is to be reimbursed in Australia’s publicly funded health system after it was cleared by a cost-effectiveness committee. The decisi ...

Journavx costs $15.50 per 50 mg tablet, taken twice daily, making it pricier than opioids. Vertex's Q4 sales hit $2.91 billion, up 16% YoY, beating the $2.78 billion consensus. Feel unsure about ...